According to Zacks, “Phreesia Inc. provides a patient intake management platform. The company’s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. “
PHR has been the topic of a number of other research reports. Chardan Capital initiated coverage on shares of Phreesia in a research note on Tuesday, July 23rd. They set a buy rating and a $33.00 price objective on the stock. William Blair initiated coverage on shares of Phreesia in a research note on Monday, August 12th. They set an outperform rating on the stock. ValuEngine lowered shares of Phreesia from a buy rating to a hold rating in a research note on Thursday, October 31st. Piper Jaffray Companies set a $33.00 price objective on shares of Phreesia and gave the company a buy rating in a research note on Tuesday, September 10th. Finally, Robert W. Baird initiated coverage on shares of Phreesia in a research note on Thursday, October 10th. They set an outperform rating and a $31.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Phreesia currently has an average rating of Buy and a consensus price target of $30.60.
PHR stock traded down $0.26 during midday trading on Thursday, reaching $29.70. 119,587 shares of the company’s stock traded hands, compared to its average volume of 272,714. The stock’s 50-day simple moving average is $27.07. Phreesia has a fifty-two week low of $22.05 and a fifty-two week high of $31.00. The company has a quick ratio of 3.52, a current ratio of 3.52 and a debt-to-equity ratio of 0.21.
Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, September 9th. The company reported ($10.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($10.30). The firm had revenue of $30.82 million for the quarter, compared to the consensus estimate of $30.05 million. On average, equities analysts forecast that Phreesia will post -0.56 EPS for the current fiscal year.
Large investors have recently modified their holdings of the stock. Emerald Advisers LLC bought a new stake in shares of Phreesia in the third quarter worth $1,036,000. Russell Investments Group Ltd. bought a new stake in shares of Phreesia in the third quarter worth $47,000. Tower Research Capital LLC TRC bought a new stake in shares of Phreesia in the third quarter worth $68,000. Rhumbline Advisers bought a new stake in shares of Phreesia in the third quarter worth $208,000. Finally, Massachusetts Financial Services Co. MA bought a new stake in shares of Phreesia in the third quarter worth $11,955,000. Institutional investors and hedge funds own 0.03% of the company’s stock.
Phreesia Company Profile
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.
Further Reading: What causes a recession?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.